The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans

Human Vaccines

Volumn 7, Issue 6, 2011, Pages 646-653

  Toneatto, Daniela ^a   Ismaili, Shevqet ^b   Ypma, Ellen ^a   Vienken, Kay ^a   Oster, Philipp ^a   Dull, Peter ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (United States)

^b Institute for Pharmacokinetic and Analytical Studies Lingornetto   (Switzerland)

Author keywords

Factor H binding protein; Meningococcal serogroup B; NadA; NHBA; Recombinant antigens

Indexed keywords

BACTERIAL ANTIGEN; BACTERIAL VACCINE; FACTOR H BINDING PROTEIN; MENINGOCOCCUS VACCINE; NEISSERIA HEPARIN BINDING PROTEIN; NEISSERIA MENINGITIDIS OUTER MEMBRANE VESICLE NORWEIGAN STRAIN; NEISSERIAL ADHESIN A PROTEIN; RECOMBINANT ANTIGEN; UNCLASSIFIED DRUG;

ACUTE APPENDICITIS; ADULT; ANTIBODY TITER; ARTHRALGIA; ARTICLE; BACTERIAL STRAIN; CHILL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; IMMUNOREACTIVITY; INFECTION PREVENTION; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; LYMPHADENOPATHY; MALAISE; MALE; MENINGOCOCCOSIS; MYALGIA; NAUSEA; NEISSERIA MENINGITIDIS; NONHUMAN; PHASE 1 CLINICAL TRIAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SALIVARY GLAND DISEASE; TOOTH PAIN; VACCINATION; VOMITING;

ADOLESCENT; ADULT; BACTERIAL OUTER MEMBRANE PROTEINS; FEMALE; HUMANS; MALE; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B; PROSPECTIVE STUDIES;

EID: 79959349259     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.6.15482     Document Type: Article

References (18)

1. Tan LK, Carlone GM, Borrow R. Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med 2010; 362:1511-20.
2. Sadarangani M, Pollard AJ. Serogroup B meningococcal vaccines - an unfinished story. The Lancet Infectious Diseases 2010; 10:112-24.
3. Holst J, Martin D, Arnold R, Huergo CC, Oster P, O'Hallahan J, Rosenqvist E. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 2009; 27:3-12.
4. Wedege E, Hoiby EA, Rosenqvist E, Bjune G. Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial. Infect Immun 1998; 66:3223-31.
5. Bjune G, Hoiby EA, Gronnesby JK, Arnesen O, Fredriksen JH, Halstensen A, et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 1991; 338:1093-6.
6. O'Hallahan J, McNicholas A, Galloway Y, O'Leary E, Roseveare C. Delivering a safe and effective strain-specific vaccine to control an epidemic of group B meningococcal disease. N Z Med J 2009; 122:48-59.
7. Giuliani MM, Adu-Bobie J, Comanducci M, Arico B, Savino S, Santini L, et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA 2006; 103:10834-9. (Pubitemid 44148381)
8. Bambini S, Muzzi A, Olcen P, Rappuoli R, Pizza M, Comanducci M. Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine 2009; 27:2794-803.
9. Giuliani MM, Biolchi A, Serruto D, Ferlicca F, Vienken K, Oster P, et al. Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus. Vaccine 2010; 28:5023-30.
10. Capecchi B, Adu-Bobie J, Di Marcello F, Ciucchi L, Masignani V, Taddei A, et al. Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells. Mol Microbiol 2005; 55:687-98.
11. Serruto D, Spadafina T, Ciucchi L, Lewis LA, Ram S, Tontini M, et al. Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proc Natl Acad Sci USA 2010; 107:3770-5.
12. Seib KL, Oriente F, Adu-Bobie J, Montanari P, Ferlicca F, Giuliani MM, et al. Influence of serogroup B meningococcal vaccine antigens on growth and survival of the meningococcus in vitro and in ex vivo and in vivo models of infection. Vaccine 2010; 28:2416-27.
13. Findlow J, Borrow R, Snape MD, Dawson M, Holland A, John MT, et al. Multicentre, open-label, randomised phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis 2010; 51:1127-37.
14. Snape MD, Dawson T, Oster P, Evans A, John MT, Ohene-Kena B, et al. Immunogenicity of Two Investigational Serogroup B Meningococcal Vaccines in the First Year of Life: A Randomized Comparative Trial. Pediatr Infect Dis J 2010; 29:71-9.
15. Donnelly J, Medini D, Boccadifuoco G, Biolchi A, Ward J, Frasch C, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci USA 2010; 107:19490-5.
16. Borrow R, Carlone GM, Rosenstein N, Blake M, Feavers I, Martin D, et al. Neisseria meningitidis group B correlates of protection and assay standardization - international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine 2006; 24:5093-107.
17. Santos GF, Giuliani M, Santini L, Adu-Bobie J, Pizza M, Rappuoli R, et al. Investigation on the effect of immune selection on resistance to bactericidal antibodies to group B meningococci in vitro. Clin Vaccine Immunol 2009; 16:1693-5.
18. Santos GF, Deck RR, Donnelly J, Blackwelder W, Granoff DM. Importance of complement source in measuring meningococcal bactericidal titers. Clin Diagn Lab Immunol 2001; 8:616-23. (Pubitemid 32428891)